Another company took an old drug and jacked up the price. Now, biotech CEOs are throwing shade

Another company took an old drug and jacked up the price. Now, biotech CEOs are throwing shade

Submitted by admin on February 23, 2020 - 1:58pm
Source: 
MedCity News
News Tags: 
Codiak Biosciences
Belcher Pharmaceuticals
FDA
505(b) pathway
Ablysinol
Headline: 
Another company took an old drug and jacked up the price. Now, biotech CEOs are throwing shade
snippet: 

Led by Codiak BioSciences CEO Douglas Williams, the CEOs criticized Belcher Pharmaceuticals, which won approval for a drug used in certain heart procedures through the FDA's 505(b)(2) pathway.

Do Not Allow Advertisers to Use My Personal information